Table 4.
The diagnostic criteria of MMP-7, TIMP-1 in combination with HE4 and CA 125 in epithelial ovarian cancer patients
| Epithelial ovarian cancer | Diagnostic criteria (%) | MMP-7 + HE4 | MMP-7 + CA125 | TIMP-1 + HE4 | TIMP-1 + CA 125 | HE4 + CA 125 | MMP-7 + HE4 + CA125 | TIMP-1 + HE4 + CA 125 |
|---|---|---|---|---|---|---|---|---|
| Stage I | SE | 71 | 63 | 54 | 42 | 63 | 75 | 63 |
| SP | 91 | 94 | 91 | 94 | 94 | 89 | 89 | |
| PPV | 74 | 79 | 68 | 71 | 79 | 72 | 68 | |
| NPV | 89 | 87 | 84 | 81 | 87 | 91 | 86 | |
| Stage II | SE | 62 | 65 | 62 | 42 | 73 | 81 | 73 |
| SP | 91 | 94 | 91 | 94 | 94 | 89 | 89 | |
| PPV | 73 | 81 | 73 | 73 | 83 | 75 | 73 | |
| NPV | 85 | 87 | 85 | 80 | 90 | 92 | 89 | |
| Stage III | SE | 96 | 92 | 88 | 85 | 96 | 100 | 100 |
| SP | 91 | 94 | 91 | 94 | 94 | 89 | 89 | |
| PPV | 81 | 86 | 79 | 85 | 86 | 79 | 79 | |
| NPV | 98 | 97 | 95 | 94 | 98 | 100 | 100 | |
| Stage IV | SE | 92 | 96 | 79 | 83 | 96 | 96 | 96 |
| SP | 91 | 94 | 91 | 94 | 94 | 89 | 89 | |
| PPV | 79 | 85 | 76 | 83 | 85 | 77 | 77 | |
| NPV | 97 | 98 | 92 | 94 | 98 | 98 | 98 | |
| Total group | SE | 80 | 81 | 71 | 63 | 82 | 88 | 83 |
| SP | 91 | 94 | 91 | 94 | 94 | 89 | 89 | |
| PPV | 93 | 95 | 92 | 94 | 95 | 93 | 92 | |
| NPV | 75 | 74 | 67 | 62 | 77 | 83 | 77 |